Takeda, Iambic partner in latest pharma AI push

“The winners over the next five years” will be the companies that “fully integrate” artificial intelligence into drug development, said Takeda research chief Andy Plump.

By Jacob Bell • Feb. 9, 2026

Small and mighty: single-domain antibodies pack a biological punch

VHH antibodies, they’re not just small, they're modular engineering platforms, capable of powerful biological activity. But with great power comes great challenges!

By Jingyuan Zhang • Feb. 9, 2026

Explore the Trendline➔

Alzheimer's disease

Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

By BioPharma Dive staff

Hims cancels plans to sell compounded GLP-1 pill after FDA backlash

Hims said it “deciding to stop offering access” to the treatment following escalating legal threats — among them a patent infringement suit Novo Nordisk filed against the company on Monday.

By Ben Fidler • Updated 11 hours ago

White House’s online service for drug sales debuts with limited impact on prices

Select products from Pfizer, Eli Lilly and others will be sold at a discount, although the lower costs won’t be felt by many Americans whose medications are covered by insurance.

By Jonathan Gardner • Feb. 6, 2026

Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game

Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie franchise and Bristol Myers pointed to a trio of narrative-changing trials.

By BioPharma Dive staff • Feb. 5, 2026

Novo, Lilly sputter as Hims launches knockoff GLP-1 pill

Novo is threatening litigation in response, while FDA head Martin Makary, without naming specific companies, said the agency would take “swift action” against those “mass-marketing illegal copycat drugs.”  

By Ben Fidler • Updated Feb. 6, 2026

Bayer details anticipated stroke prevention data for new blood-thinner

Asundexian cut the risk of an additional stroke by 26% in a large Phase 3 trial without accompanying safety issues, boosting the commercial outlook for an emerging class of anti-clotting drugs.

By Jonathan Gardner • Feb. 5, 2026

Novo shares tumble by double digits on grim sales outlook

In contrast to Lilly’s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13% decline in 2026 profits. 

By Jonathan Gardner • Feb. 4, 2026

Lilly soars again as fast-selling weight loss drugs top Wall Street projections

Despite some angst over pricing pressure for GLP-1 drugs, Lilly’s bullish projections surpassed consensus estimates, while combined 2025 sales of Zepbound and Mounjaro eclipsed $36 billion.

By Kristin Jensen • Feb. 4, 2026

Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.

By BioPharma Dive staff • Feb. 4, 2026

Pfizer dips on new data for obesity drug acquired in $10B deal

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

By Jonathan Gardner • Feb. 3, 2026

Novo combination obesity shot meets goal in diabetes trial

CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to rival Lilly's Zepbound.

By Jonathan Gardner • Feb. 2, 2026

Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials

The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of Gaucher disease.

By Delilah Alvarado • Feb. 2, 2026

GSK walks away from pioneering Wave RNA editing drug

Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because Wave is better suited to quickly advance a rare disease therapy.

By Ben Fidler • Updated Feb. 2, 2026

AstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC

The deal, which involves up to eight “next-generation” weight loss medications and could be worth more than $18 billion, ranks as the largest licensing pact of its kind since the start of 2025, according to BioPharma Dive data.

By Ben Fidler • Jan. 30, 2026

The biopharma industry outlook on 2026: Optimism and tension

A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce competition from China could short-circuit the sector's resurgence.

By Ben Fidler • Jan. 29, 2026

Sanofi expects vaccine sales growth to dip amid ‘challenging environment’

On a conference call, executives cited “confusion” and declining vaccination rates in the U.S. while discussing a quarterly sales decline and anticipated slower growth in 2026.  

By Delilah Alvarado • Jan. 29, 2026

AstraZeneca strengthens China ties with planned $15B investment

AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in dealmaking activity involving large pharmaceutical companies and their counterparts in China.

By Kristin Jensen • Jan. 29, 2026

Roche, trailing in obesity, showcases new data for GLP-1 shot

A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.

By Jonathan Gardner • Jan. 27, 2026

From detection to prevention: How sponsored testing can transform patient outcomes

Diagnostic testing has long laid the groundwork for medical decision-making.  

Jan. 26, 2026

Sanofi to seek approval of touted eczema drug despite mixed results

Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U.S. but has murky sales prospects.

By Jonathan Gardner • Jan. 23, 2026

Congress eyes tackling healthcare consolidation

“I think there’s common ground here,” one Republican congressman said Wednesday during a House Budget Committee hearing. Squaring up against healthcare monopolies would be a major pivot for the GOP.

By Rebecca Pifer Parduhn • Jan. 23, 2026

Bristol Myers buys into Janux’s ‘masked’ T cell engagers

Worth up to $850 million, the partnership provides “further validation” for Janux at a time of heightened investor scrutiny regarding the potential of its top drug, one analyst wrote. 

By Delilah Alvarado • Jan. 22, 2026

FDA lays out new path to speed development of multiple myeloma drugs

In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change that could accelerate cell therapies and other new medicines. 

By Jonathan Gardner • Jan. 22, 2026

J&J eyes $100B in sales amid gains for cancer, immune drugs

Amid patent expirations, litigation and tariff costs, J&J says it expects more growth ahead, fueled in part by its blood cancer medicines and a closely watched psoriasis pill.

By Kristin Jensen • Jan. 21, 2026